These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31834435)

  • 1. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
    Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
    Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
    Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Choi B; Kim MG; Han N; Kim T; Ji E; Park S; Kim IW; Oh JM
    Pharmacogenomics; 2015; 16(14):1585-94. PubMed ID: 26419450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
    Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
    Kim SD; Lee JH; Hur EH; Lee JH; Kim DY; Lim SN; Choi Y; Lim HS; Bae KS; Noh GJ; Yun SC; Han SB; Lee KH
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1222-30. PubMed ID: 21215809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.
    Yin J; Xiao Y; Zheng H; Zhang YC
    Bone Marrow Transplant; 2015 May; 50(5):696-705. PubMed ID: 25730183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
    Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
    Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.
    Abbasi N; Vadnais B; Knutson JA; Blough DK; Kelly EJ; O'Donnell PV; Deeg HJ; Pawlikowski MA; Ho RJ; McCune JS
    J Clin Pharmacol; 2011 Oct; 51(10):1429-38. PubMed ID: 21135089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.
    Nishikawa T; Yamaguchi H; Ikawa K; Nakayama K; Higashi E; Miyahara E; Abematsu T; Nakagawa S; Kodama Y; Tanabe T; Shigemi A; Shinkoda Y; Okamoto Y; Takeda Y; Kawano Y
    Pediatr Int; 2019 Jun; 61(6):558-565. PubMed ID: 30963629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
    Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.
    Kim MG; Kwak A; Choi B; Ji E; Oh JM; Kim K
    Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):691-703. PubMed ID: 30511436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation.
    Al-Riyami I; Al-Khabori M; Al Balushi K; Al-Zadjali S; Al-Rawahi M; Dennison D; Al-Hunaini M; Al-Rawas A; Al-Moundhri M
    Ther Drug Monit; 2022 Aug; 44(4):527-534. PubMed ID: 34990437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.
    Johnson L; Orchard PJ; Baker KS; Brundage R; Cao Q; Wang X; Langer E; Farag-El Maasah S; Ross JA; Remmel R; Jacobson PA
    J Clin Pharmacol; 2008 Sep; 48(9):1052-62. PubMed ID: 18635758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
    Ansari M; Huezo-Diaz P; Rezgui MA; Marktel S; Duval M; Bittencourt H; Cappelli B; Krajinovic M
    Bone Marrow Transplant; 2016 Mar; 51(3):377-83. PubMed ID: 26691424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
    Nava T; Rezgui MA; Uppugunduri CRS; Curtis PH; Théoret Y; Duval M; Daudt LE; Ansari M; Krajinovic M; Bittencourt H
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1918-1924. PubMed ID: 28807770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.
    Wu X; Xie H; Lin W; Yang T; Li N; Lin S; Yuan X; Ren J; Li X; Huang X
    Clin Exp Pharmacol Physiol; 2017 May; 44(5):529-538. PubMed ID: 28135768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
    Kusama M; Kubota T; Matsukura Y; Matsuno K; Ogawa S; Kanda Y; Iga T
    Clin Chim Acta; 2006 Jun; 368(1-2):93-8. PubMed ID: 16448639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.
    ten Brink MH; van Bavel T; Swen JJ; van der Straaten T; Bredius RG; Lankester AC; Zwaveling J; Guchelaar HJ
    Pharmacogenomics; 2013 Nov; 14(14):1683-90. PubMed ID: 24192117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.